Abstract
In recent years, an increasing number of investigations has demonstrated the therapeutic potential of molecules targeting the endocannabinoid system. Cannabinoids of endogenous, phytogenic, and synthetic nature have been assessed in a wide variety of disease models ranging from neurological to metabolic disorders. Even though very few compounds of this type have already reached the market, numerous preclinical and clinical studies suggest that cannabinoids are suitable drugs for the clinical management of diverse pathologies.
In this chapter, we will provide an overview of the endocannabinoid system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Clinical trials: THC in Alzheimer Disease - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Alzheimer+Disease&term=THC&cntry=&state=&city=&dist=. Accessed 7 Oct 2019.
- 2.
Clinical trials: cannabinoids in Parkinson Disease-ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Parkinson+Disease&term=cannabis&cntry=&state=&city=&dist=. Accessed 3 Oct 2019.
- 3.
Clinical trials: cannabinoids in Cancer-ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Cancer&term=cannabinoid&cntry=&state=&city=&dist= Accessed 29 June 2020.
References
Abrams DI, Guzman M (2015) Cannabis in cancer care. Clin Pharmacol Ther 97:575–586. https://doi.org/10.1002/cpt.108
Al-zoubi R, Morales P, Reggio PH (2019) Structural insights into CB1 receptor biased signaling. Int J Mol Sci 20:1837. https://doi.org/10.3390/ijms20081837
Amato G, Khan NS, Maitra R (2019) A patent update on cannabinoid receptor 1 antagonists (2015-2018). Expert Opin Ther Pat 29:261–269. https://doi.org/10.1080/13543776.2019.1597851
Andradas C, Caffarel MM, Pérez-Gómez E et al (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:245–252. https://doi.org/10.1038/onc.2010.402
Argueta DA, DiPatrizio NV (2017) Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav 171:32–39. https://doi.org/10.1016/j.physbeh.2016.12.044
Aso E, Ferrer I (2016) CB2 cannabinoid receptor as potential target against Alzheimer’s disease. Front Neurosci 10:1–10. https://doi.org/10.3389/fnins.2016.00243
Aso E, Palomer E, Juvés S et al (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J Alzheimers Dis 30:439–459. https://doi.org/10.3233/JAD-2012-111862
Aymerich MS, Aso E, Abellanas MA et al (2018) Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol 157:67–84. https://doi.org/10.1016/j.bcp.2018.08.016
Badolato M, Carullo G, Caroleo MC et al (2019) Discovery of 1,4-Naphthoquinones as a new class of Antiproliferative agents targeting GPR55. ACS Med Chem Lett acsmedchemlett 10(4):402–406. https://doi.org/10.1021/acsmedchemlett.8b00333
Balenga NA, MartÃnez-Pinilla E, Kargl J et al (2014) Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling. Br J Pharmacol 171:5387–5406. https://doi.org/10.1111/bph.12850
Balsevich G, Sticht M, Bowles NP et al (2018) Role for fatty acid amide hydrolase (faah) in the leptin-mediated effects on feeding and energy balance. Proc Natl Acad Sci U S A 115:7605–7610. https://doi.org/10.1073/pnas.1802251115
Barbado MV, Medrano M, Caballero-Velázquez T et al (2017) Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo. Int J Cancer 140:674–685. https://doi.org/10.1002/ijc.30483
Basavarajappa BS (2007) Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 5:81–97. https://doi.org/10.2174/157015907780866910
Beltramo M, Stella N, Calignano A et al (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094–1097. https://doi.org/10.1126/science.277.5329.1094
Benito C, Núñez E, Tolón RM et al (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in Neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci 23:11136–11141. https://doi.org/10.1523/JNEUROSCI.23-35-11136.2003
Benito C, Tolõn RM, Castillo AI et al (2012) β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB1 or CB2 receptors. Br J Pharmacol 166:1474–1489. https://doi.org/10.1111/j.1476-5381.2012.01889.x
Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JAS (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237–249
Berry EM, Mechoulam R (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95:185–190. https://doi.org/10.1016/S0163-7258(02)00257-7
Bifulco M, Laezza C, Pisanti S, Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148:123–135. https://doi.org/10.1038/sj.bjp.0706632
Billakota S, Devinsky O, Marsh E (2019) Cannabinoid therapy in epilepsy. Curr Opin Neurol 32:220–226. https://doi.org/10.1097/WCO.0000000000000660
Bisogno T, Hanuš L, De Petrocellis L et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852. https://doi.org/10.1038/sj.bjp.0704327
Blázquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 134:119–136. https://doi.org/10.1093/brain/awq278
Blüher M, Engeli S, Klöting N et al (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053–3060. https://doi.org/10.2337/db06-0812
Caffarel MM, Andradas C, Mira E et al (2010) Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9:196–206. https://doi.org/10.1186/1476-4598-9-196
Caffarel MM, Sarrió D, Palacios J et al (2006) Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66:6615–6621. https://doi.org/10.1158/0008-5472.CAN-05-4566
Campbell FA, Tramèr MR, Carroll D et al (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13–16
Carracedo A, Gironella M, Lorente M et al (2006) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66:6748–6755. https://doi.org/10.1158/0008-5472.CAN-06-0169
Chakravarti B, Ravi J, Ganju RK (2014) Cannabinoids as therapeutic agents in cancer : current status and future implications. Oncotarget 5:5852–5872
Chen R, Zhang J, Wu Y et al (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease. Cell Rep 2:1329–1339. https://doi.org/10.1016/j.celrep.2012.09.030
D’Ambra TE, Estep KG, Bell MR et al (1992) Conformationally restrained analogs of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124–135. https://doi.org/10.1021/jm00079a016
Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci 78:549–563. https://doi.org/10.1016/j.lfs.2005.05.055
Després J-P, Lemieux I, Alméras N (2006) Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes (Lond) 30(Suppl 1):S44–S52. https://doi.org/10.1038/sj.ijo.0803278
Devinsky O, Nabbout R, Miller I et al (2019) Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia 60:294–302. https://doi.org/10.1111/epi.14628
Devinsky O, Patel AD, Cross JH et al (2018) Effect of Cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med 378:1888–1897. https://doi.org/10.1056/NEJMoa1714631
Dhopeshwarkar A, Mackie K (2014) CB2 cannabinoid receptors as a therapeutic target - what does the future hold? Mol Pharmacol 86:430–437. https://doi.org/10.1124/mol.114.094649
Di Marzo V (2018) New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 17(9):623–639. https://doi.org/10.1038/nrd.2018.115
Di Marzo V, Fontana A, Cadas H et al (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686–691. https://doi.org/10.1038/372686a0
Di Marzo V, Stella N, Zimmer A (2015) Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 16:30–42. https://doi.org/10.1530/ERC-14-0411.Persistent
DiPatrizio NV, Astarita G, Schwartz G et al (2011) Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 108:12904–12908. https://doi.org/10.1073/pnas.1104675108
Fallon MT, Lux EA, Mcquade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy : two double-blind , randomized, placebo-controlled phase 3 studies. Br J Pain 11:119–133. https://doi.org/10.1177/2049463717710042
Fernández-Ruiz J, Romero J, Ramos JA (2015) Endocannabinoids and neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others. In: Pertwee RG (ed) Endocannabinoids. Springer International Publishing, Cham, pp 233–259
Fowler CJ (2015) Delta9-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: a critical examination of the preclinical literature. Clin Pharmacol Ther 97:587–596. https://doi.org/10.1002/cpt.84
Fraguas-Sánchez AI, Fernández-Carballido A, Torres-Suárez AI (2016) Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. Expert Opin Investig Drugs 25:1311–1323. https://doi.org/10.1080/13543784.2016.1236913
Friedman D, French JA, Maccarrone M (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol 18:504–512. https://doi.org/10.1016/S1474-4422(19)30032-8
Fu J, Bottegoni G, Sasso O et al (2011) A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 15:64–69. https://doi.org/10.1038/nn.2986
Galve-Roperh I, Sánchez C, Cortés ML et al (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313–319. https://doi.org/10.1038/73171
GarcÃa MC, Cinquina V, Palomo-Garo C et al (2015) Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett 587:1–4. https://doi.org/10.1016/j.neulet.2014.12.003
GarcÃa C, Palomo-Garo C, GarcÃa-Arencibia M et al (2011) Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson’s disease. Br J Pharmacol 163:1495–1506. https://doi.org/10.1111/j.1476-5381.2011.01278.x
GarcÃa-Arencibia M, González S, de Lago E et al (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162–170. https://doi.org/10.1016/j.brainres.2006.11.063
Gaston TE, Friedman D (2017) Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav 70:313–318. https://doi.org/10.1016/j.yebeh.2016.11.016
Giacoppo S, Bramanti P, Mazzon E (2017) Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord 17:22–31. https://doi.org/10.1016/j.msard.2017.06.015
Giuliano M, Pellerito O, Portanova P et al (2009) Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 91:457–465. https://doi.org/10.1016/j.biochi.2008.11.003
Guindon J, Lai Y, Takacs SM et al (2014) Alterations in endocannabinoid tone following chemotherapy- induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following. Pharmacol Res 67:94–109. https://doi.org/10.1016/j.phrs.2012.10.013.Alterations
Guzmán M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745–755. https://doi.org/10.1038/nrc1188
Guzmán M, Duarte MJ, Blázquez C et al (2006) A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95:197–203. https://doi.org/10.1038/sj.bjc.6603236
Guzmán M, Sánchez C, Galve-Roperh I (2002) Cannabinoids and cell fate. Pharmacol Ther 95:175–184. https://doi.org/10.1016/S0163-7258(02)00256-5
Haghani M, Shabani M, Javan M et al (2012) CB1 cannabinoid receptor activation rescues amyloid ß-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal Neurones. Cell Physiol Biochem 29:391–406. https://doi.org/10.1159/000338494
Hao E, Mukhopadhyay P, Cao Z et al (2015) Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med 21:38–45. https://doi.org/10.2119/molmed.2014.00261
Henstridge CM, Balenga NAB, Kargl J et al (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25:1835–1848. https://doi.org/10.1210/me.2011-1197
Herkenham M, Lynn AB, Johnson MR et al (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583
Hill A, Mercier M, Hill T et al (2012) Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 167:1629–1642. https://doi.org/10.1111/j.1476-5381.2012.02207.x
Hill AJ, Weston SE, Jones NA et al (2010) Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51:1522–1532. https://doi.org/10.1111/j.1528-1167.2010.02523.x
Hillard CJ, Manna S, Greenberg MJ et al (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427–1433
Hinz B, Ramer R (2019) Anti-tumour actions of cannabinoids. Br J Pharmacol 176:1384–1394. https://doi.org/10.1111/bph.14426
Huffman JW (2000) The search for selective ligands for the CB2 receptor. Curr Pharm Des 6:1323–1337
Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C et al (2018) The endocannabinoid system in mental disorders: evidence from human brain studies. Biochem Pharmacol 157:97–107. https://doi.org/10.1016/j.bcp.2018.07.009
Ibeas Bih C, Chen T, Nunn AVW et al (2015) Molecular targets of Cannabidiol in neurological disorders. Neurotherapeutics 12(4):699–730. https://doi.org/10.1007/s13311-015-0377-3
Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50–55
Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol 20:567–573
Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C (2008) The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease. Neurosci Res 61:404–411. https://doi.org/10.1016/j.neures.2008.04.011
Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53:723–728. https://doi.org/10.1007/s00262-004-0509-9
Kano M, Ohno-Shosaku T, Hashimotodani Y et al (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309–380. https://doi.org/10.1152/physrev.00019.2008
Katona I, Sperlágh B, SÃk A et al (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544–4558
Kendall DA, Yudowski GA (2017) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front Cell Neurosci 10:294. https://doi.org/10.3389/fncel.2016.00294
Khan MI, Soboci AA, Brodaczewska KK et al (2018) Involvement of the CB 2 cannabinoid receptor in cell growth inhibition and G0 / G1 cell cycle arrest via the cannabinoid agonist WIN 55, 212 – 2 in renal cell carcinoma. BMC Cancer 18:583
Kogan NM, Bl C, Alvarez L et al (2006) A cannabinoid Quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 70:51–59. https://doi.org/10.1124/mol.105.021089.cardiotoxic
Kogan NM, Rabinowitz R, Levi P et al (2004) Synthesis and antitumor activity of Quinonoid derivatives of cannabinoids. J Med Chem 47:3800–3806
Kogan NM, Schlesinger M, Peters M et al (2007) A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. J Pharmacol Exp Ther 322:646–653
Kwan P, Schachter SC, Brodie MJ (2011) Drug-Resistant Epilepsy. N Engl J Med 365:919–926. https://doi.org/10.1056/NEJMra1004418
Lastres-Becker I, Molina-Holgado F, Ramos JA et al (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 19:96–107. https://doi.org/10.1016/j.nbd.2004.11.009
Leyva-Illades D, Demorrow S (2013) Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Manag Res 5:147–155. https://doi.org/10.2147/CMAR.S35175
Ligresti A (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of Cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375–1387. https://doi.org/10.1124/jpet.106.105247
López A, Aparicio N, Pazos MR et al (2018) Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease. J Neuroinflammation 15:158. https://doi.org/10.1186/s12974-018-1174-9
Lotersztajn S, Teixeira-Clerc F, Julien B et al (2008) CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153:286–289. https://doi.org/10.1038/sj.bjp.0707511
Lotersztajn S, Teixeira-Clerc F, Mallat A, Louvet A (2011) Selective CB2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
Malfitano AM, Ciaglia E, Gangemi G et al (2011) Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15:297–308. https://doi.org/10.1517/14728222.2011.553606
Manna SSS, Umathe SN (2012) Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. Epilepsy Res 100:113–124. https://doi.org/10.1016/j.eplepsyres.2012.02.003
Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201–209. https://doi.org/10.1038/nrc747
Marsicano G, Chaouloff F (2011) Moving bliss: a new anandamide transporter. Nat Neurosci 15:5–6. https://doi.org/10.1038/nn.3011
Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against Excitotoxicity. Science (80-) 302:84–88. https://doi.org/10.1126/science.1088208
Marsicano G, Kuner R (2008) Anatomical distribution of receptors, ligands and enzymes in the brain and in the spinal cord: circuitries and neurochemistry. In: Cannabinoids and the brain. Springer US, Boston, MA, pp 161–201
MartÃn-Moreno AM, Reigada D, RamÃrez BG et al (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo : relevance to Alzheimer ’ s disease. Mol Pharmacol 79:964–973. https://doi.org/10.1124/mol.111.071290.Alzheimer
Matias I, Gonthier MP, Orlando P et al (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171–3180. https://doi.org/10.1210/jc.2005-2679
Matsuda LA, Lolait SJ, Brownstein MJ et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564. https://doi.org/10.1038/346561a0
McHugh D, Hu SSJ, Rimmerman N et al (2010) N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11:44–56. https://doi.org/10.1186/1471-2202-11-44
Mechoulam R, Ben Shabat S, Hanus L et al (1996) Endogenous cannabinoid ligands--chemical and biological studies. J Lipid Mediat Cell Signal 14:45–49
Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90. https://doi.org/10.1016/0006-2952(95)00109-D
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007) Cannabidiol--recent advances. Chem Biodivers 4:1678–1692. https://doi.org/10.1002/cbdv.200790147
Milton NGN (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci Lett 332:127–130. https://doi.org/10.1016/S0304-3940(02)00936-9
Miyato H, Kitayama J, Yamashita H et al (2009) Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res 155:40–47. https://doi.org/10.1016/j.jss.2008.06.045
Morales P, Blasco-Benito S, Andradas C et al (2015) Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J Med Chem 58:2256–2264. https://doi.org/10.1021/acs.jmedchem.5b00078
Morales P, Goya P, Jagerovic N (2018) Emerging strategies targeting CB2 cannabinoid receptor: biased agonism and allosterism. Biochem Pharmacol 157:8–17. https://doi.org/10.1016/j.bcp.2018.07.031
Morales P, Hurst DP, Reggio PH (2017) Molecular targets of the Phytocannabinoids: a complex picture. Prog Chem Org Nat Prod 103:103–131. https://doi.org/10.1007/978-3-319-45541-9_4
Morales P, Jagerovic N (2016) Advances towards the discovery of GPR55 ligands. Curr Med Chem 23:2087–2100
Morales P, Jagerovic N (2019) Antitumor cannabinoid Chemotypes: structural insights. Front Pharmacol 10:621. https://doi.org/10.3389/fphar.2019.00621
Morales P, Jagerovic N (2020) Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opin Drug Discov 00:1–14. https://doi.org/10.1080/17460441.2020.1752178
Morales P, Reggio PH (2017) An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. Cannabis Cannabinoid Res 2:265–273. https://doi.org/10.1089/can.2017.0036
Morales P, Reggio PH (2019) CBD: a new Hope? ACS Med Chem Lett 10:694–695. https://doi.org/10.1021/acsmedchemlett.9b00127
Morales P, Vara D, Goméz-Cañas M et al (2013) Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Eur J Med Chem 70:111–119
More SV, Choi D-K (2015) Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Mol Neurodegener 10:17. https://doi.org/10.1186/s13024-015-0012-0
Morell C, Bort A, Vara D et al (2016) The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis 19:248–257. https://doi.org/10.1038/pcan.2016.19
Moreno E, Andradas C, Medrano M et al (2014) Targeting CB2-GPR55 receptor Heteromers modulates cancer cell signaling. J Biol Chem 289:21960–21972. https://doi.org/10.1074/jbc.M114.561761
Müller L, Radtke A, Decker J et al (2017) The synthetic cannabinoid WIN 55,212-2 elicits death in human cancer cell lines. Anticancer Res 37:6341–6345
Murdolo G, Kempf K, Hammarstedt A et al (2007) Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Investig 30:RC17–RC21. https://doi.org/10.1007/BF03347440
Navarro G, Morales P, RodrÃguez-Cueto C et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci 10:1–11. https://doi.org/10.3389/fnins.2016.00406
Oesch S, Walter D, Wachtel M et al (2009) Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 8:1838–1845. https://doi.org/10.1158/1535-7163.MCT-08-1147
Oka S, Kimura S, Toshida T et al (2010) Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147:671–678. https://doi.org/10.1093/jb/mvp208
Pagano C, Pilon C, Calcagno A et al (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92:4810–4819. https://doi.org/10.1210/jc.2007-0768
Pan H, Mukhopadhyay P, Rajesh M et al (2009) Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 328:708–714. https://doi.org/10.1124/jpet.108.147181
Pascual D, Goicoechea C, SuardÃaz M, MartÃn MI (2005) A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118:23–34. https://doi.org/10.1016/j.pain.2005.07.008
Pellati F, Borgonetti V, Brighenti V et al (2018) Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int 2018:1–15. https://doi.org/10.1155/2018/1691428
Pérez-Gómez E, Andradas C, Flores JM et al (2013) The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 32:2534–2542. https://doi.org/10.1038/onc.2012.278
Pertwee RG (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7:E625–E654. https://doi.org/10.1208/aapsj070364
Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397–411. https://doi.org/10.1111/j.1476-5381.2008.00048.x
Pertwee RG, Howlett AC, Abood ME et al (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631. https://doi.org/10.1124/pr.110.003004
Picone RP, Kendall D (2015) Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation. Mol Endocrinol 29:801–813. https://doi.org/10.1210/me.2015-1062
Powles T, Te Poele R, Shamash J et al (2005) Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105:1214–1221. https://doi.org/10.1182/blood-2004-03-1182
Price MR, Baillie GL, Thomas A et al (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484–1495. https://doi.org/10.1124/mol.105.016162.view
Price DA, Martinez AA, Seillier A et al (2009) WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 29:2177–2186. https://doi.org/10.1111/j.1460-9568.2009.06764.x
Qamri Z, Preet A, Nasser MW et al (2009) Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 8:3117–3129. https://doi.org/10.1158/1535-7163.MCT-09-0448
Rahn EJ, Makriyannis A, Hohmann AG (2007) Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152:765–777. https://doi.org/10.1038/sj.bjp.0707333
RamÃrez BG, Blázquez C, Gómez Del Pulgar T et al (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904–1913. https://doi.org/10.1523/JNEUROSCI.4540-04.2005
Rinaldi-Carmona M, Barth F, Héaulme M et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244
Roche M, Finn DP (2010) Brain CB2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals 3:2517–2533. https://doi.org/10.3390/ph3082517
Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O (2015) Cannabinoids and epilepsy. Neurotherapeutics 12(4):747–768. https://doi.org/10.1007/s13311-015-0375-5
Rossi F, Punzo F, Umano GR et al (2018) Role of cannabinoids in obesity. Int J Mol Sci 19:2690. https://doi.org/10.3390/ijms19092690
Sarfaraz S, Adhami VM, Syed DN et al (2008) Cannabinoids for cancer treatment: progress and promise. Cancer Res 68:339–342. https://doi.org/10.1158/0008-5472.CAN-07-2785
Scherma M, Fattore L, Paola Castelli M et al (2014) The role of the Endocannabinoid system in eating disorders: neurochemical and Behavioural preclinical evidence. Curr Pharm Des 20:2089–2099
Schley M, Ständer S, Kerner J et al (2009) Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79:333–337. https://doi.org/10.1016/j.brainresbull.2009.01.011
Serrano A, Pavon FJ, Suarez J et al (2012) Obesity and the Endocannabinoid system: is there still a future for CB1 antagonists in obesity? Curr Obes Rep 1:216–228. https://doi.org/10.1007/s13679-012-0031-x
Sharkey KA, Darmani NA, Parker LA (2014) Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol 722:134–146. https://doi.org/10.1016/j.ejphar.2013.09.068
Sharma MK, Murumkar PR, Barmade MA et al (2015) A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat 25:1–24. https://doi.org/10.1517/13543776.2015.1064898
Silvestri C, Di Marzo V (2012) Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 21:1309–1322. https://doi.org/10.1517/13543784.2012.704019
Sourbron J, Schneider H, Kecskés A et al (2016) Serotonergic modulation as effective treatment for Dravet syndrome in a Zebrafish mutant model. ACS Chem Neurosci 7:588–598. https://doi.org/10.1021/acschemneuro.5b00342
Stampanoni Bassi M, Sancesario A, Morace R et al (2017) Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res 2:21–29. https://doi.org/10.1089/can.2017.0002
Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017–1030. https://doi.org/10.1002/glia.20983
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773–778. https://doi.org/10.1038/42015
Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569:501–517. https://doi.org/10.1113/jphysiol.2005.091918
Tramèr MR, Carroll D, Campbell FA et al (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J 323:16–21
Van Der Stelt M, Mazzola C, Esposito G et al (2006) Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63:1410–1424. https://doi.org/10.1007/s00018-006-6037-3
Van Esbroeck ACM, Janssen APA, Cognetta AB et al (2017) Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science (80-) 356:1084–1087. https://doi.org/10.1126/science.aaf7497
Velasco G, Hernández-Tiedra S, Dávila D, Lorente M (2016) The use of cannabinoids as anticancer agents. Prog Neuro-Psychopharmacol Biol Psychiatry 64:259–266. https://doi.org/10.1016/j.pnpbp.2015.05.010
Velasco G, Sánchez C, Guzmán M (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12:436–444. https://doi.org/10.1038/nrc3247
Vemuri VK, Makriyannis A (2015) Medicinal chemistry of cannabinoids. Clin Pharmacol Ther 97:553–558. https://doi.org/10.1111/cpt.115
Vera G, Chiarlone A, Cabezos PA et al (2007) WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 81:468–479. https://doi.org/10.1016/j.lfs.2007.06.012
Wallace MJ, Martin BR, DeLorenzo RJ (2002) Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295–301. https://doi.org/10.1016/S0014-2999(02)02331-2
Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428:51–57. https://doi.org/10.1016/S0014-2999(01)01243-2
Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137–143. https://doi.org/10.1007/s00520-002-0387-7
Williams CM, Whalley BJ, McCabe C (2015) Cannabinoids and appetite (dys)regulation. In: Fattore L (ed) Cannabinoids in neurologic and mental disease. Elsevier, pp 315–339
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592. https://doi.org/10.1038/35069076
Xian X, Huang L, Zhang B et al (2016) WIN 55,212-2 inhibits the epithelial Mesenchymal transition of gastric cancer cells via COX-2 signals. Cell Physiol Biochem 39:2149–2157. https://doi.org/10.1159/000447910
Xu D, Wang J, Zhou Z et al (2015) Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells. Mol Med Rep 12:7963–7970. https://doi.org/10.3892/mmr.2015.4477
Yadav MR, Murumkar PR (2018) Advances in patented CB1 receptor antagonists for obesity. Pharm Pat Anal 7:169–173. https://doi.org/10.4155/ppa-2018-0020
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Morales, P., Reggio, P.H. (2021). Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models. In: Murillo-Rodriguez, E., Pandi-Perumal, S.R., Monti, J.M. (eds) Cannabinoids and Neuropsychiatric Disorders. Advances in Experimental Medicine and Biology, vol 1264. Springer, Cham. https://doi.org/10.1007/978-3-030-57369-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-57369-0_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57368-3
Online ISBN: 978-3-030-57369-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)